• Jul. 19, 2019 (PDF/80KB)Corporate

  Comments on Announcement by Australian Stem Cell and Regenerative Medicine Company

• Jul. 09, 2019 (PDF/340KB)CSR

  Sumitomo Dainippon Pharma and National Center for Global Health and Medicine Initiate International Project on Measures against Antimicrobial Resistance (AMR) and Promote the Proper Use of Antibiotics in Vietnam

• Jul. 02, 2019 (PDF/125KB)R&D

  Sumitomo Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Pancreatic Cancer Following Interim Analysis

• Jun. 25, 2019 (PDF/169KB)R&D

  Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes

• Jun. 18, 2019 (PDF/87KB)Products

  Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical Antipsychotic LONASEN Tape in Japan

more